Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lasofoxifene - Sermonix Pharmaceuticals

Drug Profile

Lasofoxifene - Sermonix Pharmaceuticals

Alternative Names: CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; Oporia

Latest Information Update: 11 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Pfizer; Sermonix Pharmaceuticals
  • Class Antineoplastics; Naphthalenes; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Cannabinoid receptor CB2 inverse agonists; Estrogen receptor alpha modulators; Estrogen receptor beta agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Postmenopausal osteoporosis
  • Preregistration Atrophic vaginitis
  • Phase III Breast cancer
  • Phase II Female sexual dysfunction
  • Research Ovarian cancer
  • No development reported Hypogonadism

Most Recent Events

  • 03 Jun 2019 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 55th American Society of Clinical Oncology Annual Meeting (ASCO-2019)
  • 28 May 2019 Lasofoxifene - Sermonix Pharmaceuticals receives Fast Track designation for Breast cancer [PO,Tablet] (Late-stage disease, Metastatic disease) in USA
  • 10 Dec 2018 Sermonix Pharmaceuticals plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease) in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top